Navigation Links
VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Date:8/12/2008

SAN FRANCISCO, Aug. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer of VIA, will present a company update at the Fourth Annual Noble Financial Equity Conference at 8:00 a.m. PT on Tuesday, August 19, 2008 at the Loews Lake Las Vegas Resort in Nevada.

Interested parties may access a live webcast including a virtual slide presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay will be archived on the VIA website for at least one week following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

About Noble Financial

Noble Financial is a privately-held, full-service capital markets firm driven by what is often overlooked by other firms -- uncovering the value embedded in the orphaned, undiscovered or misunderstood company. The company focuses on converting market inefficiencies into profit opportunities. Noble Financial supports emerging companies through strategic advice, investment banking, market-making, sales & trading, comprehensive equity research, and the development of institutional support. Noble Financial's equity conferences -- 2008 marks their fourth annual -- allow for a unique blend of professional and personal interaction among a diverse cross-section of executives. The company has operated for 24 years and has offices in Florida, New York City and Boston.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery ... announced today the appointment of a new Chairman, Mr ... Carmine , effective immediately. James Garner , ... Executive Director and former Acting CEO, Mr Iain Ross ... Non-Executive Director. --> James Garner , has also ...
(Date:2/4/2016)... ... 04, 2016 , ... Shimadzu Scientific Instruments will showcase several ... and poster sessions, and present on the analysis of mycotoxins and medical cannabis ... to 10 at the Georgia World Congress Center in Atlanta, Georgia. , ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
Breaking Biology Technology:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... -- Various factors have contributed to the rise ... and biosimilars. Some of these factors include the ... for cost-effective alternatives, growing burden of chronic diseases, ... of their corresponding patented biologic drugs, and are ... efficacy. The global biosimilars market is estimated to ...
Breaking Biology News(10 mins):